Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target
MIRM Analyst Ratings
Strong Buy
12Buy0Hold0Sell
Based on 12 analysts giving stock ratings to Mirum Pharmaceuticals in the past 3 months
MIRM Stock 12 Month Forecast
Average Price Target
MXN 2,865.84▲(93.37% Upside)Based on 12 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is MXN 2,865.84 with a high forecast of MXN 3,710.92 and a low forecast of MXN 2,412.10. The average price target represents a 93.37% change from the last price of MXN 1,482.03.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 3.71K
AverageMXN 2.87K
LowMXN 2.41K
Highest Price TargetHighestMXN 3,710.92Average Price TargetMXN 2,865.84Lowest Price TargetLowestMXN 2,412.10
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Swayampakula Ramakanth | H.C. Wainwright | MXN 3,710.92 | buy | 150.39%Upside | Reiterated | 10/27/26 | ||
| Joseph Thome | TD Cowen | MXN 2,597.64→MXN 2,690.42 | buy | 81.54%Upside | Reiterated | 10/21/26 | ||
| James Condulis | Stifel Nicolaus | MXN 2,523.43→MXN 2,894.52 | buy | 95.31%Upside | Reiterated | 10/15/26 | ||
| Yigal Nochomovitz | Citi | MXN 2,968.74→MXN 3,414.05 | buy | 130.36%Upside | Reiterated | 10/13/26 | ||
| Michael Ulz | Morgan Stanley | MXN 2,541.98→MXN 2,820.30 | buy | 90.30%Upside | Reiterated | 10/13/26 | ||
| Gavin Clark-Gartner | Evercore ISI | MXN 2,504.87→MXN 2,708.97 | buy | 82.79%Upside | Reiterated | 10/13/26 | ||
| Jessica Fye | J.P. Morgan | ― | buy | ― | Reiterated | 10/12/26 | ||
| Lisa Walter | RBC Capital | MXN 2,504.87→MXN 2,875.96 | buy | 94.06%Upside | Reiterated | 10/08/26 | ||
| Brian Skorney | Robert W. Baird | MXN 2,282.22→MXN 2,412.10 | buy | 62.76%Upside | Reiterated | 09/29/26 | ||
| Joseph Schwartz | Leerink Partners | MXN 2,857.41 | buy | 92.80%Upside | Reiterated | 09/28/26 | ||
| Jonathan Wolleben | Citizens JMP | MXN 2,708.97→MXN 2,541.98 | buy | 71.52%Upside | Reiterated | 08/06/26 | ||
| Joshua Schimmer | Cantor Fitzgerald | MXN 2,597.64 | buy | 75.28%Upside | Assigned | 08/05/26 | ||
| Kalpit Patel | Wolfe Research | MXN 2,690.42 | buy | 81.54%Upside | Initiated | 05/19/26 | ||
| Ryan Deschner | Raymond James | MXN 3,042.95→MXN 3,061.51 | buy | 106.58%Upside | Reiterated | 05/07/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Swayampakula Ramakanth | 10/27/26 | MXN 3,710.92 | buy | 150.39%Upside | Reiterated | H.C. Wainwright | ||
| Joseph Thome | 10/21/26 | MXN 2,597.64→MXN 2,690.42 | buy | 81.54%Upside | Reiterated | TD Cowen | ||
| James Condulis | 10/15/26 | MXN 2,523.43→MXN 2,894.52 | buy | 95.31%Upside | Reiterated | Stifel Nicolaus | ||
| Yigal Nochomovitz | 10/13/26 | MXN 2,968.74→MXN 3,414.05 | buy | 130.36%Upside | Reiterated | Citi | ||
| Michael Ulz | 10/13/26 | MXN 2,541.98→MXN 2,820.30 | buy | 90.30%Upside | Reiterated | Morgan Stanley | ||
| Gavin Clark-Gartner | 10/13/26 | MXN 2,504.87→MXN 2,708.97 | buy | 82.79%Upside | Reiterated | Evercore ISI | ||
| Jessica Fye | 10/12/26 | ― | buy | ― | Reiterated | J.P. Morgan | ||
| Lisa Walter | 10/08/26 | MXN 2,504.87→MXN 2,875.96 | buy | 94.06%Upside | Reiterated | RBC Capital | ||
| Brian Skorney | 09/29/26 | MXN 2,282.22→MXN 2,412.10 | buy | 62.76%Upside | Reiterated | Robert W. Baird | ||
| Joseph Schwartz | 09/28/26 | MXN 2,857.41 | buy | 92.80%Upside | Reiterated | Leerink Partners | ||
| Jonathan Wolleben | 08/06/26 | MXN 2,708.97→MXN 2,541.98 | buy | 71.52%Upside | Reiterated | Citizens JMP | ||
| Joshua Schimmer | 08/05/26 | MXN 2,597.64 | buy | 75.28%Upside | Assigned | Cantor Fitzgerald | ||
| Kalpit Patel | 05/19/26 | MXN 2,690.42 | buy | 81.54%Upside | Initiated | Wolfe Research | ||
| Ryan Deschner | 05/07/26 | MXN 3,042.95→MXN 3,061.51 | buy | 106.58%Upside | Reiterated | Raymond James |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Mirum Pharmaceuticals
3 Months
Success Rate12/17 ratings generated profit
71%
Average Return
+12.98%
Copying Gavin Clark-Gartner's trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +12.98% per trade.
1 Year
Success Rate20/23 ratings generated profit
87%
Average Return
+48.39%
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +48.39% per trade.
2 Years
Success Rate20/23 ratings generated profit
87%
Average Return
+111.23%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 86.96% of your transactions generating a profit, with an average return of +111.23% per trade.
MIRM Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 13 | 12 | 5 | 6 | 16 |
| Buy | 17 | 13 | 17 | 17 | 16 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 30 | 25 | 22 | 23 | 32 |
In the current month, MIRM has received 32 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 2,865.84.
MIRM Financial Forecast
HighMXN 0.98
ConsensusMXN -9.15
LowMXN -16.35
MIRM Earnings Forecast
Next quarter’s earnings estimate for MIRM is -MXN 9.15 with a range of -MXN 16.35 to MXN 0.98. The previous quarter’s EPS was -MXN 19.92. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 3.41B
ConsensusMXN 3.35B
LowMXN 3.2B
MIRM Sales Forecast
Next quarter’s sales forecast for MIRM is MXN 3.35B with a range of MXN 3.20B to MXN 3.41B. The previous quarter’s sales results were MXN 3.31B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
MIRM Stock Forecast FAQ
What is MX:MIRM’s average 12-month price target, according to analysts?
Based on analyst ratings, Mirum Pharmaceuticals’s 12-month average price target is Mex$2,865.84.
What is MX:MIRM’s upside potential, based on the analysts’ average price target?
Mirum Pharmaceuticals has 93.37% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Mirum Pharmaceuticals a Buy, Sell or Hold?
Mirum Pharmaceuticals has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Mirum Pharmaceuticals’s share price target?
The average share price target for Mirum Pharmaceuticals is Mex$2,865.84. This is based on 12 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$3,710.92, and the lowest forecast is Mex$2,412.10. The average share price target represents a 93.37% increase from the current price of Mex$1,482.03.
What do analysts say about Mirum Pharmaceuticals?
Mirum Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of Mirum Pharmaceuticals?
To buy shares of MX:MIRM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
